Fasiglifam

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameFasiglifam
Drug Alias Name法西格列泛Fasiglifamum法格列凡Fasiglifam hemihydrateTAK-875
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFree fatty acid receptor 1 agonists
TargetsFree fatty acid receptor 1
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes MellitusCardiovascular Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[36] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTakeda Pharmaceutical Co LtdTakeda Pharmaceutical (China) Company Limited
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Diabetes MellitusCardiovascular Diseases +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG